BCOR Antibodies

Structure of BCOR

BCOR is a relatively large nucleoprotein with a molecular weight of approximately 175 kDa. Its molecular weight is highly conserved across different species, mainly due to the well-preserved key functional domains in chromatin regulation. This protein is composed of 1,674 amino acids and adopts a multi-domain organizational form, including the BCOR motif at the N-terminal, the ANK repeat sequence in the middle, and the PUFD domain at the C-terminal. BCOR interacts with proteins such as PCGF1 through ANK repeat sequences to form the core framework of the PRC1.1 complex, and its PUFD domain directly participates in the deubiquitination regulation of histone H2A. These structural features enable BCOR to act as a scaffold protein to coordinate the assembly and function of epigenetic modification complexes, which is crucial for maintaining gene silencing and cell differentiation.

Fig. 1 Structure and functional domains of BCOR.¹

Key structural properties of BCOR:

• Multi-domain organizational form, including BCOR motif, ANK repeat sequence and PUFD functional domain
• ANK repeat regions mediate specific protein interactions
• PUFD domains specifically recognize histones and participate in epigenetic regulation

Functions of BCOR

The core function of the BCOR gene is to regulate epigenetic modifications as a transcriptional co-suppressor. In addition, it is also involved in a variety of key cellular processes, including cell differentiation, developmental regulation and tumor suppression.

BCOR specifically recognizes histone modifications through its C-terminal PUFD domain and forms complexes with multiple epigenetic regulatory factors to precisely regulate gene expression in a synergistic manner. This mechanism is significantly different from the traditional sequence-specific transcription factor action mode.

Applications of BCOR and BCOR Antibody in Literature

1. Fayoumi, Abdulkareem. "BCOR abnormalities in endometrial stromal sarcoma." Gynecologic Oncology Reports (2025): 101672. https://doi.org/10.1016/j.gore.2024.101672

The article indicates that BCOR gene abnormalities (such as fusion or mutation) are key features of high-grade endometrial stromal sarcoma, affecting diagnosis and prognosis. Molecular testing can assist in identification. Surgery combined with radiotherapy and chemotherapy is the main therapy, and treatment strategies targeting BCOR and related pathways are under exploration.

2. Tauziède-Espariat, Arnault, et al. "CNS tumor with EP300:: BCOR fusion: discussing its prevalence in adult population." Acta neuropathologica communications 11.1 (2023): 26. https://doi.org/10.1186/s40478-023-01523-y

The article indicates that EP300::BCOR fusion in CNS tumors is a newly discovered type, more common in adults. Its clinical, imaging and pathological features are different from the common BCOR internal duplication (ITD) in children, and it may become a new subtype in the future WHO classification.

3. Ebrahimi, Azadeh, et al. "BCOR: CREBBP fusion in malignant neuroepithelial tumor of CNS expands the spectrum of methylation class CNS tumor with BCOR/BCOR (L1)-fusion." Acta Neuropathologica Communications 12.1 (2024): 60. https://doi.org/10.1186/s40478-024-01780-5

The article indicates that BCOR/BCORL1 fusion type CNS tumors are a new subtype defined recently through methylation analysis, and their diagnosis still needs to combine molecular and histological features. This article reports for the first time a case of adult BCOR::CREBBP fusion and, based on the literature, presents the typical characteristics of this type of tumor, emphasizing the importance of complementary molecular testing for diagnosis.

4. Kelly, Madison J., et al. "Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis." Nature communications 10.1 (2019): 1347. https://doi.org/10.1038/s41467-019-09250-6

The article indicates that BCOR gene mutations are associated with the occurrence of acute myeloid leukemia. Mouse model studies have shown that the absence of BCOR can lead to abnormal differentiation of hematopoietic stem cells, expansion of myeloid progenitor cells, and synergistic induction of aggressive leukemia with carcinogenic KrasG12D. The mechanism is related to the dysregulation of PRC1 target genes (such as Hoxa7/9).

5. Rompietti, Chiara, et al. "Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice." Leukemia (2025): 1-12. https://doi.org/10.1038/s41375-025-02557-y

The article indicates that BCOR deletion can work in synergy with NOTCH1 activation to drive the transformation of chronic lymphocytic leukemia (CLL) into aggressive Richter (RT). In mouse models, Bcor absence accelerates lymphoid proliferation and alters the tumor microenvironment, while NOTCH1 inhibition reduces tumor infiltration and prolongs survival, suggesting targeting potential.

Creative Biolabs: BCOR Antibodies for Research

Creative Biolabs specializes in the production of high-quality BCOR antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom BCOR Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our BCOR antibodies, custom preparations, or technical support, contact us at email.